Stock Analysis, Dividends, Split History

RGRX / RegeneRx Biopharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.31
Volume11,100.00
Market Cap ($M)37.09
Enterprise Value ($M)36.16
Book Value ($M)-2.26
Book Value / Share-0.02
Price / Book-19.04
NCAV ($M)-2.26
NCAV / Share-0.02
Price / NCAV-18.95
Share Statistics
Common Stock Shares Outstanding 109,789,703
Common Shares Outstanding 114,936,762
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.07
Return on Assets (ROA)0.33
Return on Equity (ROE)-0.05
Balance Sheet (mrq) ($M)
Assets0.71
Liabilities2.97
Quick Ration/a
Current Ratio0.94
Income Statement (mra) ($M)
Sponsored Research Revenue0.00
Revenues56,652.00
Operating Income-1.44
Net Income0.29
Earnings Per Share Diluted0.00
Earnings Per Share Basic0.00
Cash Flow Statement (mra) ($M)
Cash From Operations-0.66
Identifiers and Descriptors
CUSIP75886X108
Central Index Key (CIK)707511

Split History

Stock splits are used by RegeneRx Biopharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Your Daily Pharma Scoop: Epizyme Down, MiMedx Proceeds, Summit Beats

2018-08-05 seekingalpha
Epizyme down 8% premarket on termination of tazemetostat in DLBCL & delay in NDA filing for ES (42-2)

CUSIP: 75886X108